Medicure (CVE:MPH) and Emerald Health Therapeutics (CVE:EMH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Medicure and Emerald Health Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Medicure | 0 | 0 | 0 | 0 | N/A |
Emerald Health Therapeutics | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Medicure and Emerald Health Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Medicure | N/A | N/A | N/A |
Emerald Health Therapeutics | N/A | N/A | N/A |
Earnings and Valuation
This table compares Medicure and Emerald Health Therapeutics' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Medicure | C$12.71 million | 1.32 | C$-16,188,599.00 | C($1.55) | -1.03 |
Emerald Health Therapeutics | C$13.02 million | 4.17 | C$-142,699,488.00 | C($0.70) | -0.38 |
Medicure has higher earnings, but lower revenue than Emerald Health Therapeutics. Medicure is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Emerald Health Therapeutics beats Medicure on 4 of the 5 factors compared between the two stocks.